This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heartfailure patient on February 13, 2024 at Henry Ford Hospital in Detroit. However, only about 8,000 tricuspid valvesurgeries are performed annually.
The Intrepid TMVR is a heartvalve that is designed to help alleviate mitral regurgitation so that blood can flow through the heart in the intended direction,” said Matthew Saybolt , M.D., FACC, principal site investigator and medical director, Structural Heart Disease Program, Jersey Shore University Medical Center.
Traditionally, cardiothoracic surgeons have repaired or replaced the tricuspid valve during open-heartsurgery and only when absolutely necessary; such surgeries are complex and risky. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery.
The potential to detect aortic stenosis through our IH technology is an exciting development that brings us a step closer to achieving the MindMics purpose to one day eliminate heartfailure as the leading cause of death globally (similar to what glucose monitoring has done to transform diabetes)." "We
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heartvalve, for which more than 1.6 TR occurs when the valve doesn't close properly, causing a leak and allowing blood to flow backward in the heart. Abbott has announced U.S million people in the U.S.
Delivered through a vein in the leg, TriClip's TEER technology works by clipping together a portion of the leaflets – or flaps of tissue – to repair the tricuspid valve and help blood flow in the right direction without the need for open-heartsurgery.
Tricuspid regurgitation (TR) is a common and serious disease for which openheartsurgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to openheartsurgery is severely restricted and is not considered an option for most patients with TR.
Traditionally, cardiothoracic surgeons have repaired or replaced the tricuspid valve during open-heartsurgery and only when absolutely necessary; such surgeries are complex and risky. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content